All Stories

  1. Three-Phase Serum Concentration Kinetics of FGF23 in a Clinical Model of Acute Myocardial Infarction
  2. Expression of circulating miRNA before and after abdominal aneurysm repair
  3. Case Series Evaluating the Relationship of SGLT2 Inhibition to Pulmonary Artery Pressure and Non-Invasive Cardiopulmonary Parameters in HFpEF/HFmrEF Patients—A Pilot Study
  4. SIGNed explanations: Unveiling relevant features by reducing bias
  5. Rising and Falling High‐Sensitivity Cardiac Troponin in Diagnostic Algorithms for Patients With Suspected Myocardial Infarction
  6. Personalized diagnosis in suspected myocardial infarction
  7. Hemodynamic markers of pulmonary vasculopathy for prediction of early right heart failure and mortality after heart transplantation
  8. Outcomes After Early Postoperative Myocardial Infarction Due to Graft Failure in Patients Undergoing Coronary Artery Bypass Grafting
  9. Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension
  10. Regional extracellular volume within late gadolinium enhancement-positive myocardium to differentiate cardiac sarcoidosis from myocarditis of other etiology: a cardiovascular magnetic resonance study
  11. Right Ventricular Strain by Magnetic Resonance Feature Tracking Is Largely Afterload-Dependent and Does Not Reflect Contractility: Validation by Combined Volumetry and Invasive Pressure Tracings
  12. Presepsin Predicts 1-Year All-Cause Mortality Better Than N-Terminal Pro-B-Type Natriuretic Peptide in Patients Undergoing Transcatheter Aortic Valve Implantation
  13. Gdf-15 and Soluble St2 As Biomarkers of Right Ventricular Dysfunction in Pulmonary Hypertension
  14. Exercise MR-proANP unmasks latent right heart failure in CTEPH
  15. Use of serial changes in biomarkers vs. baseline levels to predict left ventricular remodelling after STEMI
  16. Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension
  17. Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy
  18. A conceptual framework for establishing trust in real world intelligent systems
  19. Osteopontin and Galectin-3 As Biomarkers of Maladaptive Right Ventricular Remodeling In Pulmonary Hypertension
  20. A proposal for implementation of the chest pain unit model in Greece
  21. Association Between Primary Coronary Slow-Flow Phenomenon and Epicardial Fat Tissue
  22. An Experiment Environment for Definition, Training and Evaluation of Electrocardiogram-Based AI Models
  23. CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension
  24. Detecting myocardial scar using electrocardiogram data and deep neural networks
  25. Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH
  26. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension
  27. Pregnancy-associated plasma protein A – a new indicator of pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension?
  28. The adipokine fatty-acid binding protein 4 and cardiac remodeling
  29. Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions – Comparison of uremic, hypertensive and hypertrophic cardiomyopathy
  30. SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension
  31. Myeloid-related protein 8/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction
  32. High-Content Immunophenotyping and Hierarchical Clustering Reveal Sources of Heterogeneity and New Surface Markers of Human Blood Monocyte Subsets
  33. Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes
  34. Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA
  35. GDF-15 as a risk stratification biomarker for cardiovascular disease
  36. Prognostic Value of a Novel and Established High-Sensitivity Troponin I Assay in Patients Presenting with Suspected Myocardial Infarction
  37. Prognostic performance of the ESC SCORE and its German recalibrated versions in primary and secondary prevention
  38. Impact of Vascular Function on Maximum Power Output in Elite Handball Athletes
  39. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction
  40. Identification of acute myocardial infarction in elderly patients using optimized highly sensitive troponin I thresholds
  41. Development of renal function during staged balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension
  42. Troponinwerte und der akute Myokardinfarkt
  43. Bone marrow and plasma FGF‐23 in heart failure patients: novel insights into the heart–bone axis
  44. Identification and regulation of the long non-coding RNA Heat2 in heart failure
  45. High-sensitivity cardiac troponin assays: finally ready for prime time?
  46. Anti-citrullinated protein antibodies are not associated with extent of disease or prognosis in patients with coronary artery disease
  47. Right bundle branch block in patients with suspected myocardial infarction
  48. Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease
  49. Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance Hemodialysis
  50. N-terminal pro–B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
  51. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs
  52. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation
  53. Troponin I Assay for Identification of a Significant Coronary Stenosis in Patients with Suspected Acute Myocardial Infarction and Wide QRS Complex
  54. Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain
  55. Influence of hypothermia and subsequent rewarming upon leukocyte-endothelial interactions and expression of Junctional-Adhesion-Molecules A and B
  56. Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model
  57. Strategies to overcome misdiagnosis of type 1 myocardial infarction using high sensitive cardiac troponin assays
  58. Identification of acute myocardial infarction in patients with atrial fibrillation and chest pain with a contemporary sensitive troponin I assay
  59. Estimation of Values below the Limit of Detection of a Contemporary Sensitive Troponin I Assay Improves Diagnosis of Acute Myocardial Infarction
  60. Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease
  61. Assessment of microRNAs in patients with unstable angina pectoris
  62. From heart to toe: Heart's contribution on peripheral microRNA levels
  63. Dialyse- und Ultrafiltrationsverfahren bei kardio-renalem Syndrom. Empfehlung der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. und der Deutschen Gesellschaft für Nephrologie e.V.
  64. Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction
  65. Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study
  66. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis
  67. Defining a reference population to determine the 99th percentile of a contemporary sensitive cardiac troponin I assay
  68. Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population
  69. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease
  70. Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application
  71. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study
  72. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation
  73. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain
  74. Prognostic Information of Glycogen Phosphorylase Isoenzyme BB in Patients With Suspected Acute Coronary Syndrome
  75. Diagnostic and Prognostic Performance of Myeloperoxidase Plasma Levels Compared With Sensitive Troponins in Patients Admitted With Acute Onset Chest Pain
  76. Cardiac troponin determination in the diagnosis of acute myocardial infarction
  77. Serial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction
  78. Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the Absence of Acute Coronary Syndrome
  79. Midregional Proadrenomedullin for Prediction of Cardiovascular Events in Coronary Artery Disease: Results from the AtheroGene Study
  80. Reduktion der stationären Verweildauer bei Patienten mit akutem Koronarsyndrom durch Einrichtung einer Chest Pain Unit
  81. Interventionelle renale Sympathikusdenervation zur Behandlung der therapieresistenten Hypertonie
  82. A Genome-Wide Association Study Identifies LIPA as a Susceptibility Gene for Coronary Artery Disease
  83. Making it More Sensitive
  84. Novel biomarkers in evaluation of acute coronary syndrome
  85. Tako-Tsubo syndrome: dying of a broken heart?
  86. Distribution and Categorization of Left Ventricular Measurements in the General Population
  87. Patientenzufriedenheit beim akuten Koronarsyndrom
  88. Copeptin Improves Early Diagnosis of Acute Myocardial Infarction
  89. Improved outcome in acute coronary syndrome by establishing a chest pain unit
  90. Rolle von Biomarkern zur Risikostratifizierung in der Prävention kardiovaskulärer Erkrankungen
  91. Entwicklung der Chest-Pain-Units in Deutschland
  92. Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial Infarction
  93. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study
  94. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study
  95. Chest Pain Unit (CPU): erste Erfahrungen in Mainz
  96. Color Doppler Indices of Renal Allografts Depend on Vascular Stiffness of the Transplant Recipients